Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution.
Satake H, Yoshino T, Sasaki T, Bando H, Yoda Y, Ikematsu H, Kojima T, Fuse N, Zenda S, Doi T, Kaneko K, Ohtsu A. Satake H, et al. Among authors: sasaki t. Jpn J Clin Oncol. 2012 Sep;42(9):861-4. doi: 10.1093/jjco/hys093. Epub 2012 Jun 19. Jpn J Clin Oncol. 2012. PMID: 22717459
Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
Nakano S, Yuki S, Kawamoto Y, Nakatsumi H, Ando T, Kajiura S, Yoshikawa A, Harada K, Hatanaka K, Tanimoto A, Ishiguro A, Honda T, Dazai M, Sasaki T, Sakamoto N, Komatsu Y. Nakano S, et al. Among authors: sasaki t. Int J Clin Oncol. 2020 Oct;25(10):1800-1806. doi: 10.1007/s10147-020-01720-y. Epub 2020 Jul 14. Int J Clin Oncol. 2020. PMID: 32666389 Free PMC article.
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Komatsu Y, Yoshino T, Yamazaki K, Yuki S, Machida N, Sasaki T, Hyodo I, Yachi Y, Onuma H, Ohtsu A. Komatsu Y, et al. Among authors: sasaki t. Invest New Drugs. 2014 Jun;32(3):473-80. doi: 10.1007/s10637-013-0056-3. Epub 2013 Dec 15. Invest New Drugs. 2014. PMID: 24337768 Free PMC article. Clinical Trial.
Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.
Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N. Kobayashi Y, et al. Among authors: sasaki t. Future Oncol. 2015;11(4):617-27. doi: 10.2217/fon.14.251. Future Oncol. 2015. PMID: 25686117 Clinical Trial.
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
Nakano S, Kawamoto Y, Yuki S, Harada K, Miyagishima T, Sogabe S, Dazai M, Sato A, Ishiguro A, Nakamura M, Kajiura S, Takahashi Y, Tateyama M, Hatanaka K, Tsuji Y, Sasaki T, Shindo Y, Kobayashi T, Yokota I, Sakamoto N, Sakata Y, Komatsu Y. Nakano S, et al. Among authors: sasaki t. BMJ Open. 2022 May 9;12(5):e048833. doi: 10.1136/bmjopen-2021-048833. BMJ Open. 2022. PMID: 35534074 Free PMC article.
9,386 results